Master the skills necessary to rise to the ever-evolving challenges of the pharmaceutical patent endgame.

Each fall, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes Master Symposium in Chicago to receive up-to-the-minute information on the latest developments affecting Hatch-Waxman litigation and participate in significant peer-to-peer networking opportunities.

As the industry prepares to address the fallout of global pharmaceutical patent losses of billions of dollars and the impact of evolving law, regulation and policy impacting the Hatch-Waxman landscape, the time for this conference has never been more relevant.


Get judicial insights on the complex challenges facing both brand name and generic drug manufacturers:

Northern District of Illinois

Ruben Castillo
Chief Judge

Sidney I. Schenkier

District of Delaware

Christopher Burke

District of New Jersey

Douglas E. Arpert
Magistrate Judge

Jose L. Linares
Chief Judge

Eastern District of Texas

Roy Payne
Magistrate Judge


Hear from the PTAB on the latest practices and protocols for pharmaceutical patent litigators:

Jacqueline D. Wright Bonilla
Vice Chief Administrative Patent Judge
Michelle N. Ankenbrand
Administrative Patent Judge


Hear from the FTC on the latest antitrust developments impacting Paragraph IV litigation:

Lauren Peay
Federal Trade Commission (FTC)


Hear industry insights from:

  • Abbvie
  • Akorn Pharmaceuticals
  • Amneal Pharmaceuticals
  • Association for
    Accessible Medicines
  • Astellas Pharma US, Inc.
  • Avanir Pharmaceuticals, Inc.
  • Baxter Healthcare
  • Eagle Pharmaceuticals
  • Eli Lilly & Company
  • Fresenius Kabi USA
  • Gilead Sciences
  • Glenmark Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Shire Pharmaceuticals
  • Unified Patents


Meet All the Speakers

Featured Topics for October 2018 Include:

  • The Nexus Between Pricing and Patents in the Hatch-Waxman Landscape
  • Evolving Venue and Jurisdiction Challenges Following TC Heartland
  • New §101 Challenges Affecting Method of Use Patents
  • Evolving Tests for Induced Infringement
  • Emerging FDA Initiatives Impacting Hatch-Waxman and Paragraph IV Litigation

  • Effective Economic Strategies for ANDA Litigation Management
  • Changes in PTAB Practice in the Aftermath of SAS
  • The Aftermath of Helsinn and Post-AIA On-Sale Bar Considerations
  • The Continuing Sovereign Immunity Saga


View the Agenda

Attend this event and you will gain much-needed advantage over the competition as well as the necessary skills to rise to the ever-evolving challenges of the costly and ruthless patent endgame. Register Now!

Register Now

Join our mailing list to stay up-to-date with new announcement on speakers and agenda.

Event Contacts

For sponsorship opportunities please contact:
Esther Fleischhacker
Tel: 212-352-3220 x5232
[email protected]
For media partnership opportunities please contact:
Linda Lam
Tel: 212-352-3220 ext. 5538
[email protected]
For questions about this year’s program/content, or information on how you can speak next year please contact:
Nicole Pitti
Tel: 212.352.3220 ext. 5534
[email protected]

Who you will meet

Patent attorneys and litigators (in-house & law firm) who represent:

Brand name pharmaceutical companies

Generic pharmaceutical companies

Biopharmaceutical companies



Are you involved in IP Due Diligence? You may also be interested in:

Life Sciences IP Due Diligence
Master best practices for assessing, valuing, and commercializing IP assets

November 29-30, 2018
Boston, MA

Connect With Us